Oppenheimer Downgrading Teva As They No Longer See A Clear Path To Return To Growth in A Timely Manner And Cont. Pricing Pressure In U.S. Generics Makes Firm Less Optimistic That Its U.S. Generics Business Will Meet Or Exceed Street's Expectations In 2H17